Headache as a tirzepatide side effect: what the evidence says

What the trial data and official guidance actually recorded

The SURMOUNT-1 trial (which enrolled 2,539 adults with obesity across 72 weeks) documented headache as one of the adverse events occurring across the treatment groups. The tirzepatide prescribing information, published on the electronic Medicines Compendium, categorises headache among the recognised side effects of the medicine. The NHS tirzepatide medicines page confirms this, describing headache as a side effect some people experience, particularly early in treatment or after a dose step.

One misconception worth setting down gently: headache doesn't mean the medicine is damaging anything. In most cases it reflects the body responding to changes in gastric motility, appetite, fluid intake and caloric shift rather than any direct toxic effect on the nervous system. That doesn't make the headache any less real, but it does change how you approach it.

The pattern seen in clinical practice mirrors the trial data. Headaches tend to cluster around the first week of a new dose and ease considerably once the system has acclimatised. At lower doses they're generally milder; at 7.5mg or above some people notice them returning briefly before settling again. For most, they're a nuisance rather than a reason to stop, and our tirzepatide headache treatment guidance covers the practical steps prescribers most commonly recommend. You can read more about the broader tirzepatide side effects profile to see where headache sits relative to the commoner gastrointestinal symptoms.

Why dehydration deserves more attention than it usually gets

Tirzepatide reduces appetite significantly. It also slows gastric emptying. Both effects mean some people simply drink less without noticing, fewer sips alongside meals, fewer casual drinks between them. On top of that, nausea and occasional vomiting in the early weeks can tip fluid balance further. The result: headache driven not by the drug's direct mechanism but by mild dehydration sitting beneath it.

This is probably the most underappreciated trigger for headaches on GLP-1 and dual-agonist treatment. Recognising it matters because the fix is straightforward: consistent, deliberate fluid intake throughout the day, aiming for pale-yellow urine as a practical guide. Caffeine withdrawal is worth flagging too, reduced appetite sometimes leads people to skip their usual morning coffee, which brings its own headache within hours.

A headache that appears the day after a dose is particularly worth thinking about through a hydration lens. If a careful fluid intake for 24 hours reduces it markedly, that's useful information for your prescriber. The broader context of Mounjaro side effects (tirzepatide's brand name in the UK) gives more detail on how the gastrointestinal effects and hydration interact across the treatment period.

When to get medical help without delay

The MHRA's Yellow Card scheme exists so that real-world side effect patterns can be monitored beyond the controlled trial setting. Reporting a headache there, particularly if it's unusual or persistent, contributes to the ongoing safety surveillance that keeps this medicine's profile accurate. It is also worth knowing that in January 2026 the MHRA issued a Drug Safety Update specifically addressing GLP-1 medicines and acute pancreatitis, a condition whose earliest symptom can be severe upper abdominal pain radiating to the back, occasionally accompanied by vomiting. This is distinct from a headache, but the update is a useful reminder that not every symptom on treatment is routine.

Seek prompt medical attention if your headache is the worst you have ever had, comes on suddenly and very severely, is accompanied by visual disturbance, confusion, weakness or speech difficulty, or does not respond to usual measures and is getting worse. These are not the typical presentation of a tirzepatide-related headache, but they are the features that warrant urgent clinical assessment regardless of what medicine you are taking. If you are uncertain whether your symptoms need urgent review, contact your GP or call 111. Our clinical team is available for aftercare seven days a week, details on the contact page.

For a more detailed look at the headache and Mounjaro relationship, including practical management approaches, that page covers what our prescribers find most useful to share. People who want to understand the headache from Mounjaro in greater depth, including how frequency and severity typically change over time, will find that page a useful companion to their consultation notes. Suitability for treatment (and how to navigate side effects if they arise) is discussed during your consultation with a named GPhC-registered prescriber at nume's treatment page.